458 related articles for article (PubMed ID: 25004168)
1. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
2. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Dean J; Panainte C; Khan N; Singh D
Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
[TBL] [Abstract][Full Text] [Related]
3. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
Bulac S; Cimrin A; Ellidokuz H
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
[TBL] [Abstract][Full Text] [Related]
5. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
6. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
8. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
Singh D; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
[TBL] [Abstract][Full Text] [Related]
10. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
11. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/formoterol.
Vos W; De Backer J; Poli G; De Volder A; Ghys L; Van Holsbeke C; Vinchurkar S; De Backer L; De Backer W
Respiration; 2013; 86(5):393-401. PubMed ID: 23595105
[TBL] [Abstract][Full Text] [Related]
12. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
13. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
[TBL] [Abstract][Full Text] [Related]
14. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta
Pirina P; Foschino Barbaro MP; Paleari D; Spanevello A
Respir Med; 2018 Oct; 143():74-81. PubMed ID: 30261996
[TBL] [Abstract][Full Text] [Related]
15. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
[TBL] [Abstract][Full Text] [Related]
16. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
[TBL] [Abstract][Full Text] [Related]
17. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
[TBL] [Abstract][Full Text] [Related]
18. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
Postma DS; Roche N; Colice G; Israel E; Martin RJ; van Aalderen WM; Grigg J; Burden A; Hillyer EV; von Ziegenweidt J; Gopalan G; Price D
Int J Chron Obstruct Pulmon Dis; 2014; 9():1163-86. PubMed ID: 25378918
[TBL] [Abstract][Full Text] [Related]
19. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.
Vos W; Hajian B; De Backer J; Van Holsbeke C; Vinchurkar S; Claes R; Hufkens A; Parizel PM; Bedert L; De Backer W
Int J Chron Obstruct Pulmon Dis; 2016; 11():263-71. PubMed ID: 26917956
[TBL] [Abstract][Full Text] [Related]
20. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
